UP!

IOSP $122.95

IOSP target price
122.95
0
0
Innospec Inc.
Type
Public company
Traded as NASDAQ: IOSP
S&P 600 Component
Industry Oil and gas
Headquarters United States
Products Specialty chemicals
Number of employees
1,300
Website www.innospecinc.com

Innospec Inc., formerly known as Octel Corporation and Associated Octel Company, Ltd., is a global specialty chemical company. It comprises three business units: Fuel Specialties, responsible for the development and supply of additives for fuels and which also includes the company's activities in its Oilfield Chemicals division, Performance Chemicals, which focuses on products for the Personal Care industry and also provides products for the Polymers markets, and Octane Additives, which is the last remaining non-Chinese producer of tetraethyllead (TEL) used in the manufacture of motor gasoline in one remaining country and 100LL avgas throughout the world.The company has recently sparked controversy due to it being the only company which continues to export leaded petrol from the UK to Algeria despite pledging to stop several times and direct links to childhood brain damage and premature death.

Innospec is headquartered in Englewood, Colorado, and has major regional centers in the United Kingdom and Singapore, along with international offices and processing facilities in China, UAE, Cyprus, South Korea, and India.[1]

Production plants are located in multiple countries including UK, France, Germany, Philippines, and the United States.

The company has around 1300 employees located in 20 countries.

Innospec has made the following recent acquisitions and divestments:

Innospec markets detergents, cold flow improvers, lubricity improvers, corrosion inhibitors, antioxidants, cetane improvers, TEL, and a range of other chemicals as fuel additives.

The Oilfield Services division provides products and services for drilling, fracturing & stimulation and production operations to customers in the oil and gas industry

In Personal Care, the company makes a range of high performance surfactants, emollients and silicone formulations.

In 2007 US authorities alerted the UK SFO to Innospec's activities which had come to their attention via a UN committee and a complaint filed with SEC involving their Iraqi agents and former company executives. In a 2010 investigation by The Guardian and Guardian Films, Innospec, while trading as company Octel, was revealed to have been bribing officials in Iraq and Indonesia with millions of dollars in order to continue using TEL as a fuel additive, which causes brain damage in children through elevated lead levels. The company negotiated a global settlement, although this was condemned by Lord Justice Thomas of the UK during sentencing. In October 2014 the convictions of Miltiades Papachristos and Dennis Kerrison for conspiracy to corrupt were upheld against appeals. The company was released from its Monitor supervision and successfully completed its parole period in early 2015.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2022 2022-10-31 Future report Set alerts
Q2 2022 2022-08-02 1.58 1.58
Q1 2022 2022-05-03 1.53 1.53
Q4 2021 2022-02-15 1.30 1.30
Q3 2021 2021-11-02 1.15 1.15
Q2 2021 2021-08-03 1.30 1.30
Q1 2021 2021-05-04 1.06 1.06
Q4 2020 2021-02-16 1.27 1.27
Q3 2020 2020-11-03 0.00 0.00
Q2 2020 2020-08-04 -0.18 -1.62

Ratings

2016-04-05 Upgrade KeyBanc Sector Weight to Overweight $53.00
2016-04-05 Upgrade KeyCorp Sector Weight to Overweight $53.00
2015-10-12 Downgrade Monness Crespi & Hardt Buy to Neutral
2015-05-01 Initiated Coverage Singular Research Buy $60.00
2014-02-14 Boost Price Target Monness Crespi & Hardt Buy $46.00 to $53.00
2014-02-14 Downgrade CJS Securities Market Perform
2013-11-12 Downgrade KeyBanc Buy to Hold
2013-02-14 Reiterated Monness Crespi & Hardt Buy $40 to $46
2007-11-16 Upgrade JP Morgan Neutral to Overweight
2007-06-20 Downgrade Matrix Research Buy to Hold
2007-04-20 Downgrade Matrix Research Buy to Hold
2016-04-05 Upgrade KeyBanc Sector Weight to Overweight $53.00
2016-04-05 Upgrade KeyCorp Sector Weight to Overweight $53.00
2015-10-12 Downgrade Monness Crespi & Hardt Buy to Neutral
2015-05-01 Initiated Coverage Singular Research Buy $60.00
2014-02-14 Boost Price Target Monness Crespi & Hardt Buy $46.00 to $53.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks